Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences Inks $25.6M and $15M Loan Agreements

NEW YORK (GenomeWeb) – Exact Sciences said in a document filed with the US Securities and Exchange Commission today that it has inked revolving and non-revolving loan agreements with MB Financial Bank.

The revolving loan agreement provides Exact Sciences with a 24-month secured revolving credit facility of up to $15.0 million with a Dec. 10, 2019 maturity date.

Amounts borrowed under the revolving loan agreement accrue interest at one of three yearly rates elected by Exact Sciences. They are the sum of the one-month Libor rate plus 2 percent; the sum of the three-month Libor rate plus 2 percent; and the MB Bank Reference Rate minus .5 percent.

The firm noted that it anticipates using the loan to fund facility renovation, development and construction projects, and other general working-capital activities.

The non-revolving construction loan agreement inked by Exact Sciences subsidiary GC Growth with MB Bank provides up to $25.6 million with a maturity date of Dec. 10, 2022. The agreement bears interest at a rate equal to the sum of the one-month Libor rate plus 2.25 percent.

Exact said in the SEC document that it expects to use that loan to finance the construction of a clinical laboratory and related facilities, and to conduct additional development of a 46-acre campus in Madison, Wisconsin. As a condition of the agreement, Exact is required to invest at least $16.4 million of its cash in the construction project. 

The Scan

Time to Act

A new report urges the UK to consider regulations to protect against the misuse of genomic technologies, according to the Guardian.

Fulgent Seeking Defamation Suit

Fulgent Genetics says it plans to sue Los Angeles County Sheriff Alex Villanueva for defamation, the Los Angeles Times reports.

Speeding Gene-Edited Crops

Reuters reports that China's new trial rules will make it easier to grow gene-edited crops there.

Nucleic Acids Research Papers on Viral Recombination, Pan-Cancer Mutations, SARS-CoV-2 Variability

In Nucleic Acids Research this week: updated pipeline to detect viral recombination, mutational patterns in tumor samples, and more.